文献速递脑血管病

糖尿病卒中患者取栓后使用SGLT2i与功能结局

Sodium-Glucose Cotransporter 2 Inhibitor Use and Functional Outcomes After Endovascular Thrombectomy in Diabetic Stroke
RSS 订阅 · Stroke

本研究为多中心回顾性队列研究,纳入2020年1月至2025年3月韩国、意大利、瑞士4个综合卒中中心接受血管内取栓的糖尿病急性缺血性卒中患者429例。其中51例(11.9%)在取栓后使用SGLT2i。结果显示,取栓后使用SGLT2i与3个月mRS评分改善相关。

要点

  • 取栓后使用SGLT2i的糖尿病患者3个月功能结局更好。
  • overlap加权模型中良好功能结局(mRS 0-2)的比值比为2.26。
  • SGLT2i可能成为卒中后糖尿病管理的潜在治疗选择。

核心结论

  • 糖尿病急性缺血性卒中患者取栓后使用SGLT2i与3个月功能结局改善相关。

研究设计与样本

  • 回顾性队列研究,分析2020年1月至2025年3月韩国、意大利、瑞士4个综合卒中中心的前瞻性收集数据。
  • 纳入429例接受血管内取栓的糖尿病急性缺血性卒中患者。
  • 采用overlap加权、逆概率治疗加权和1:1倾向评分匹配三种倾向评分方法。

主要发现

  • 51例(11.9%)患者在取栓后使用SGLT2i。
  • overlap加权模型(每组加权n=37)中,SGLT2i使用与3个月mRS评分分布改善相关,共同比值比2.31(95%CI 1.30-4.10)。
  • SGLT2i使用与良好功能结局(mRS 0-2)相关,比值比2.26(95%CI 1.15-4.43)。
  • 逆概率治疗加权分析中SGLT2i使用与优良功能结局(mRS 0-1)显著相关。

关键数值与推荐

  • 良好功能结局定义为3个月mRS评分0-2分。
  • 优良功能结局定义为3个月mRS评分0-1分。
  • 成功再通率为85.3%。

临床怎么用

  • 糖尿病急性缺血性卒中患者取栓后可考虑使用SGLT2i,但需等待前瞻性试验证实。

局限性

  • 回顾性观察性设计无法确立因果关系。
  • SGLT2i使用组样本量仅51例。
  • 可能存在未测量的混杂因素和选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stroke, Volume 57, Issue 11, Page 3259-3267, November 1, 2026. BACKGROUND:Although preclinical studies and limited clinical evidence suggest potential benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) after acute ischemic stroke, their effects in patients with moderate-to-severe acute ischemic stroke requiring endovascular thrombectomy remain unclear. This study aimed to evaluate whether SGLT2i use after endovascular thrombectomy is associated with improved 3-month functional outcomes in diabetic patients with acute ischemic stroke.METHODS:This retrospective cohort study analyzed prospectively collected data from January 2020 to March 2025 across 4 comprehensive stroke centers in Korea, Italy, and Switzerland. Consecutive adult patients with diabetes were grouped according to whether SGLT2i was used after their endovascular thrombectomy. Propensity score–based methods—including overlap weighting, inverse probability of treatment weighting, and 1:1 propensity score matching—were applied. Outcomes included the shift in 3-month modified Rankin Scale score, favorable (modified Rankin Scale score 0–2), and excellent outcomes (modified Rankin Scale score 0–1) at 3 months. Ordinal and binary logistic regression analyses were performed.RESULTS:Of 429 eligible patients (mean [SD] age, 73.5 [11.1] years; 249 [58.0%] men; median [interquartile range] initial National Institutes of Health Stroke Scale score, 12 [6–18]), 51 (11.9%) received SGLT2i poststroke. Successful recanalization was achieved in 85.3%. In the overlap weighting model (weighted n=37 per group), SGLT2i use was associated with improved 3-month modified Rankin Scale score distribution (common odds ratio, 2.31; [95% CI, 1.30–4.10]) and higher odds of a favorable outcome (odds ratio, 2.26; [95% CI, 1.15–4.43]). Results were consistent across inverse probability of treatment weighting and propensity score matching models, with inverse probability of treatment weighting analyses additionally demonstrating significant associations with excellent outcomes. No significant effect modification was observed across key clinical subgroups.CONCLUSIONS:Poststroke SGLT2i therapy after endovascular thrombectomy was associated with improved 3-month functional outcomes in this multicenter retrospective analysis of diabetic patients. These findings suggest a potential therapeutic role for SGLT2i in poststroke diabetes management and support future prospective trials.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Stroke:Sodium-Glucose Cotransporter 2 Inhibitor Use and Functional Outcomes After Endovascular Thrombectomy in Diabetic Stroke

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。